RAD001 Plus Bevacizumab in Metastatic Melanoma

Phase 2

Completed

• Conditions: Metastatic Melanoma
• Interventions: Drug: Bevacizumab; Drug: Everolimus

• Registration Number: NCT00591734
• Lead Sponsor: SCRI Development Innovations, LLC

Brief Summary

This is a non-randomized, open label Phase II study comparing bevacizumab and everolimus in the treatment of metastatic melanoma.

Detailed Description

All patients will begin treatment with the same doses of RAD001 and bevacizumab. Patients will receive 6 weeks of treatment, followed by re evaluation. Patients with objective response or stable disease will continue treatment until disease progression.

During the study, all patients will receive 10 mg of RAD001 orally daily and 15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.

Fifty-five patients will be enrolled in this multi-centered study

Study Timeline

• Study First Submitted: 2007-12-26
• Study First Submitted QC: 2007-12-26
• Study Start: 2008-01
• Study First Posted: 2008-01-11
• Primary Completion: 2010-10
• Study Completion: 2011-10
• Results First Submitted: 2013-01-22
• Results First Submitted QC: 2013-01-22
• Results First Posted: 2013-02-26
• Status Verified: 2021-11
• Last Update Submitted: 2021-11-22
• Last Update Posted: 2021-11-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 57

Inclusion Criteria

1. Histologically confirmed melanoma.
2. Unresectable stage IV disease, or recurrent disease with metastases.
3. Measurable disease (by Response Evaluation Criteria in Solid Tumors [RECIST]) or measurable skin lesions.
4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
5. Life expectancy >=12 weeks.
6. Patients are allowed 0-2 prior treatment regimens containing chemotherapy and/or immunotherapy (interferon, interleukin 2).
7. Women of childbearing potential must have a negative serum pregnancy test with 7 days before beginning treatment.
8. Absolute neutrophil count (ANC) >=1500/µL, and platelets >=100,000/µL.
9. Serum creatinine <=2.0 mg/dL.
10. Serum bilirubin <=1.5 mg/dL institutional upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5 × ULN or <5 × ULN in patients with documented liver metastases.

Exclusion Criteria

1. Previous treatment with bevacizumab or other anti-angiogenesis agents.

2. Previous treatment with mTOR inhibitors.

3. Drugs or substances known to be inhibitors or inducers of the isoenzyme CYP3A are not allowed.

4. Treatment with investigational agents within 4 weeks of study entry.

5. Treatment with more than two previous chemotherapy regimens.

6. Immunization with attenuated live vaccines within one week of study or anytime during study treatment period.

7. Female patients who are pregnant or breastfeeding.

8. Central nervous system (CNS) involvement by metastatic melanoma.

9. CNS disease (e.g., seizures not controlled with standard medical therapy, history of stroke).

10. Any severe and/or uncontrolled medical conditions or other conditions that could affect participation in the study such as:

    • Severely impaired lung function.
    • Uncontrolled diabetes as defined by fasting serum glucose >1.5 ULN,
    • Any acute or chronic uncontrolled infection/disorder.
    • Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardize by the treatment with the study therapy.
    • Any acute or chronic uncontrolled infection/disorder.
    • Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardize by the treatment with the study therapy.
    • Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.

11. Acute myocardial infarction (MI) with the previous 6 months.

12. Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, New York Heart Association [NYHA] Class II or greater congestive heart failure [CHF], serious cardiac arrhythmia requiring medication), or >= grade 2 vascular disease.

13. Clinical history of hemoptysis or hematemesis.

14. Clinical evidence or history of a bleeding diathesis or coagulopathy.

15. Major surgical procedures, fine-needle aspirations, or core biopsies with 7 days of starting treatment.

16. Patients with PEG tubes or G-tubes.

17. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).

18. Proteinuria at screening as demonstrated by either

    1. Urine protein:creatinine (UPC) ratio >= 1.0 at screening OR
    2. Urine dipstick for proteinuria >= 2+ (patients discovered to have >=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate <= 1g of protein in 24 hours to be eligible).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Intervention	Bevacizumab	All patients received bevacizumab 15 mg/kg, administered by intravenous (IV) infusion on day 1 of each 21 day course. In addition, patients received everolimus 10 mg orally on a daily basis.
Intervention	Everolimus	All patients received bevacizumab 15 mg/kg, administered by intravenous (IV) infusion on day 1 of each 21 day course. In addition, patients received everolimus 10 mg orally on a daily basis.

Primary Outcome Measures

Name	Time	Method
Progression-free Survival	13 months	Length of time, in months, that patients were alive from their first date of protocol treatment until worsening of their disease

Secondary Outcome Measures

Name	Time	Method
Overall Survival Rate	1 year	Overall Survival is defined as the length of time, in months, that patients were alive from their first date of protocol treatment until death. For patients who were alive at the time of calculation, follow-up time was censored at date of last contact. The percentage of patients who were alive at 1 year is reported here. This was estimated using the Kaplan Meier method.
Objective Response Rate (ORR)	13 months	The percentage of patients who experience an objective benefit from treatment (CR+PR). The response categories were assigned using RECIST criteria. Complete Response (CR) = Disappearance of all target lesions ; Partial Response (PR) = \>=30% decrease in the sum of the longest diameter of target lesions.

Trial Locations

Locations (15)

Watson Clinic Center for Cancer Care and Research; 🇺🇸 Lakeland, Florida, United States

Oncology Hematology Associates of SW Indiana; 🇺🇸 Evansville, Indiana, United States

Florida Hospital Cancer Institute; 🇺🇸 Orlando, Florida, United States

Florida Cancer Specialists; 🇺🇸 Fort Myers, Florida, United States

St. Louis Cancer Care; 🇺🇸 Chesterfield, Missouri, United States

Chattanooga Oncology & Hematology Associates; 🇺🇸 Chattanooga, Tennessee, United States

South Texas Oncology and Hematology; 🇺🇸 San Antonio, Texas, United States

Virginia Cancer Institute; 🇺🇸 Richmond, Virginia, United States

Gulfcoast Oncology Associates; 🇺🇸 Saint Petersburg, Florida, United States

Center for Cancer and Blood Disorders; 🇺🇸 Bethesda, Maryland, United States

Grand Rapids Clinical Oncology Program; 🇺🇸 Grand Rapids, Michigan, United States

Methodist Cancer Center; 🇺🇸 Omaha, Nebraska, United States

Tennessee Oncology, PLLC; 🇺🇸 Nashville, Tennessee, United States

Consultants in Medical Oncology and Hematology; 🇺🇸 Drexel Hill, Pennsylvania, United States

Northeast Georgia Medical Center; 🇺🇸 Gainesville, Georgia, United States